Lasa Supergenerics has announced to collaborate with the Institute of Chemical Technology, (ICT) to commence the development of antiviral drug favipiravir for the treatment of Covid19.
The companies are working towards the research and scale-up activity of favipiravir and would be taking necessary steps for getting permission from the Drug Controller General of India (DCGI) to launch the product in Indian market at the earliest.
“Once the favipiravir therapy is approved by global regulatory authorities we would approach Drug Controller General of India (DCGI) for conducting required bioequivalence clinical trials in India and also seek for strategic private investments and/or government aid to commercialise this product subject to all regulatory approvals and trials,” informed Dr Omkar Herlekar, Chairman of Lasa Supergenerics.
Favipiravir is an antiviral drug that possesses activity against many RNA viruses. It is a guanine analogue approved for influenza treatment. It can effectively inhibit the RNA-dependent RNA polymerase enzyme of RNA viruses like influenza, Ebola, yellow fever, chikungunya, norovirus and enterovirus.